The Gates of Hell: Excessive Somnolence and Excessive Quantity of Sleep Prevalence, Comorbidity and Mortality


Scope of the Meeting


Why a meeting on Excessive Somnolence (ES) and Excessive Quantity of Sleep (EQS)? Hypersomnolence (the DSM-5 is replacing Hypersomnia Disorders by Hypersomnolence Disorders) is a broad diagnostic term and includes symptoms of Excessive Quantity of Sleep (e.g., extended nocturnal sleep or involuntary daytime sleep) and Excessive Somnolence (e.g. deteriorated quality of wakefulness as a sleep propensity during wakefulness and an inability to remain awake when required). The change from Sleepiness to Somnolence is not only cosmetic for one of the main problems encountered in the study of Excessive Daytime Sleepiness is the lack of uniformity of its definition. Somnolence is more accurate in the fact that its main expression is easily understandable and directly linked with the Hypersomnolence Disorder as recently defined by the DSM-5.

While there is a mounting evidence of the high prevalence of Excessive Somnolence in the community, its meaning in term of medical/psychological consequences remains understudied. There is a growing trend in labeling Excessive Somnolence as a disease or a disorder. So far, there is no data supporting this claim. Excessive Somnolence is not a disease or a disorder: it is a symptom of a sleep disorder or of another disease and for sure part of Hypersomnolence Disorder. There is some scientific evidence linking Excessive Somnolence to cognitive deficits and Excessive Quantity of Sleep to increased mortality risk in the community, but the links with specific sleep disorders remain to be established.

During this meeting, the participants will discuss on several aspects related to comorbidity, mortality and the mechanisms involved in Hypersomnolence Disorders. At the end of this meeting we will have a clearer picture on how we should orient our research efforts to improve our understanding of Hypersomnolence, how it should be measured and what we still have to learn in order to improve the quality of life of people complaining of Excessive Somnolence or Excessive Quantity of Sleep.

Program

Friday, April 27th, 2012

08:15 - 08:30 Maurice Ohayon, MD, DSc, PhD, Chair
Welcome / Overview of the meeting
 
08:30 - 09:05 Maurice Ohayon, MD, DSc, PhD
Excessive Somnolence and Excessive Quantity of Sleep - Prevalence, Comorbidity, Mortality
 
09:05 - 09:40 Michael Thorpy, MD Sleepiness: Terminology, and often an enigma with a difficult Differential Diagnosis
 
09:40 - 09:55 Discussion
Are longitudinal and familial surveys able to identify predictive factors and/or vulnerability factors of Excessive Somnolence ?
Long And Short Sleepers: link with somnolence and Sleeping too Much.
Sleeping Too much:Are Mental Disorders a risk factor?
Medical Disorders and relationship with Hypersomnolence
 
09:55 - 10:10 Break
 
10:10 - 10:45 Jed Black, MD
Narcolepsy, Sleepiness and Sleep
 
10:45 - 11:20 Tood Swick, MD
Patients with Hypersomnia in a dedicated Sleep Practice
 
11:20 - 11:55 Andrew Krystal, MD, MSc
Are Psychotropic Drugs Triggers for Excessive Somnolence? Comorbidity with Mental Disorders.
 
11:55 - 12:10 Discussion
Genetic, mental and iatrogenic vulnerability for Excessive Somnolence
How is the Sleep of Narcoleptic probands?
A familial pattern of quantity of sleep?
Familial links with Sleeping Too Much and Sleepiness?
Risk and Benefits of Psychotropic Drugs
 
12:10 - 13:15 Lunch
 
13:15 - 13:50 Yves Dauvilliers, MD, PhD
Excessive Daytime Sleepiness and Cardio-Vascular Risks
 
13:50 - 14:25 Jacques Montplaisir, MD, PhD
Hypersomnolence in Patients with Parkinson Disease and other Neurological Conditions
 
14:25 - 14:55 Rafael Pelayo, MD
Hypersomnolence in Children
 
14:55 - 15:30 Michael Vitiello, PhD
Sleeping Too Much and Excessive Sleepiness in the Elderly.
 
15:30 - 15:45 Discussion
Risk Factors of Hypersomnolence Disorders
Cardio-Vascular Risks and Consequences for Hypersomnolent Patients1
Neurological Disorders associated with Hypersomnolence: Their severity
Excessive Somnolence and Elderly people
How to help research on Risk Factors and Mortality of Hypersomnolence Disorders
 
15:30 - 15:45 Break
 
15:45 - 16:00 Tom Roth, PhD
Prevalence and Consequences of Disturbed Sleep Among Rotating Shift Workers
 
16:00 - 16:35 Giuseppe Plazzi, MD, PhD
Co-morbidities in Childhood Narcolepsy with Cataplexy
 
16:35 - 17:10 Richard Bogan, MD
Pharmacodynamic Model for Treatment of Narcolepsy
 
17:45 - 18:05 Discussion
Sleepiness and Shift Workers
Role of the medications in Hypersomnia Disorders
Place of Narcolepsy in the Hypersomnolence Disorders
Narcolepsy and children in Classifications
 
18:05 - 18:40 Maurice Ohayon, MD, DSc, PhD, Chair
General Discussion
Place of Hypersomnolence and Narcolepsy in the DSM-5
Future directions of Research
Conclusions

Abstracts

Click here

This Activity is supported by an Educational grant from Jazz Pharmaceuticals to Stanford University.